Dermata Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Dermata Therapeutics Director Kathleen D. Scott acquired 11 shares of common stock for $1.19 per share.
NASDAQ
Dermata Therapeutics' SVP of Regulatory Affairs, Maria E. Bedoya-Toro Munera, plans to acquire 1,000 shares of common stock at $1.27 per share on February 17, 2026.
NASDAQ
Dermata Therapeutics' SVP of Regulatory Affairs, Maria E Bedoya-Toro Munera, was granted 9,000 stock options with an exercise price of $2.18.
NASDAQ
Dermata Therapeutics Director Kathleen D. Scott acquired 2,500 stock options with an exercise price of $2.18, vesting monthly over one year.
NASDAQ
Dermata Therapeutics, Inc. granted 18,000 stock options to Senior VP and CDO Christopher J. Nardo with an exercise price of $2.18.
NASDAQ
Dermata Therapeutics Director Andrew Seth Sandler was granted 2,500 stock options with an exercise price of $2.18, vesting monthly over one year.
NASDAQ
Dermata Therapeutics' President, CEO, and Chairman, Gerald T. Proehl, reported the acquisition of 37,500 stock options with an exercise price of $2.18.
NASDAQ
Dermata Therapeutics Director Wendell Wierenga was granted 2,500 stock options with an exercise price of $2.18, vesting over 12 months.
NASDAQ
Dermata Therapeutics, Inc. Director David F. Hale was granted 2,500 stock options with an exercise price of $2.18, vesting monthly over one year.
NASDAQ
Dermata Therapeutics Director Steven J Mento was granted 2,500 stock options with an exercise price of $2.18, vesting monthly over one year.
NASDAQ
Dermata Therapeutics' SVP and CFO, Kyri K. Van Hoose, was granted 18,000 stock options with an exercise price of $2.18, vesting over four years.
NASDAQ
Dermata Therapeutics Director Brittany Bradrick was granted 2,500 stock options with an exercise price of $2.18, vesting over 12 months.
NASDAQ
Dermata Therapeutics, Inc. director Mary Fisher was granted 2,500 stock options with an exercise price of $2.18, vesting monthly over one year.
NASDAQ
Dermata Therapeutics' SVP and CFO, Kyri K. Van Hoose, acquired common stock and warrants in a private placement, adjusting an existing warrant's exercise price.
NASDAQ
Dermata Therapeutics CEO Gerald T. Proehl acquired common stock and warrants in a private placement and amended an existing warrant, increasing his beneficial ownership.
NASDAQ
Director Mary Fisher purchased shares of common stock and warrants in Dermata Therapeutics via a private placement.
NASDAQ
Kyri K. Van Hoose, SVP and CFO of Dermata Therapeutics, acquired 78,741 shares of common stock and accompanying warrants in a private placement on January 21, 2025.
NASDAQ
Gerald T. Proehl, CEO and Chairman of Dermata Therapeutics, purchased shares of common stock and warrants in a private placement.
NASDAQ
Director David F. Hale acquired shares of common stock and warrants in Dermata Therapeutics through a private placement.
NASDAQ
Andrew Seth Sandler, a director at Dermata Therapeutics, acquired 5,000 stock options on January 13, 2025.
NASDAQ
Dermata Therapeutics' Senior VP, Christopher J. Nardo, acquired 20,000 stock options at an exercise price of $1.38 on January 13, 2025.
NASDAQ
Director Brittany Bradrick acquired 5,000 stock options in Dermata Therapeutics, Inc. on January 13, 2025.
NASDAQ
Maria E. Bedoya-Toro, SVP of Regulatory Affairs at Dermata Therapeutics, acquired 8,000 stock options on January 13, 2025.
NASDAQ
David F. Hale, a director at Dermata Therapeutics, acquired 5,000 stock options on January 13, 2025.
NASDAQ
Dermata Therapeutics director Wendell Wierenga acquired 5,000 stock options at an exercise price of $1.38 on January 13, 2025.
NASDAQ
A Dermata Therapeutics director, Mary Fisher, acquired 5,000 stock options on January 13, 2025, at an exercise price of $1.38.
NASDAQ
Dermata Therapeutics' CFO, Kyri K. Van Hoose, was granted 20,000 stock options on January 13, 2025.
NASDAQ
Dermata Therapeutics' CEO, Gerald T. Proehl, was granted 45,000 stock options on January 13, 2025, according to a recent SEC filing.
NASDAQ
A Dermata Therapeutics director, Steven J Mento, acquired 5,000 stock options on January 13, 2025.
NASDAQ
Kathleen D. Scott, a director at Dermata Therapeutics, acquired 5,000 stock options on January 13, 2025.